End-of-day quote
Other stock markets
|
||
- USD | - |
02:10pm | Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M | MT |
01:58pm | Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M | MT |
Sales 2024 * | 12.63M 9.21M 737M | Sales 2025 * | 13.59M 9.92M 794M | Capitalization | 667M 487M 38.95B |
---|---|---|---|---|---|
Net income 2024 * | -113M -82.46M -6.6B | Net income 2025 * | -130M -94.86M -7.59B | EV / Sales 2024 * | 52.8 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 49.1 x |
P/E ratio 2024 * |
-6.12
x | P/E ratio 2025 * |
-5.15
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.66% |
Latest transcript on Arbutus Biopharma Corp
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 30/06/14 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 10/06/18 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 30/11/14 | |
James Meyers
BRD | Director/Board Member | 58 | 22/10/18 |
Daniel Burgess
BRD | Director/Board Member | 62 | 22/03/17 |
1st Jan change | Capi. | |
---|---|---|
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-17.02% | 31.47B | |
+54.44% | 25.24B | |
-12.94% | 15.82B | |
-9.12% | 11.96B | |
-15.62% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |